



**NCIC CLINICAL TRIALS GROUP  
2013 Spring Meeting of Participants**

**SPECIAL PLENARY SESSION**

**Friday, April 26, 2013**

**4:30 – 6:00 pm**

**AGENDA**

4:30 – 4:35	Welcome and Introductions	Dr. Ralph Meyer
4:35 – 4:50	A Phase II Study of PX-866 in Patients With Metastatic Castration Resistant Prostate Cancer	Dr. Sebastien Hotte
4:50 – 5:05	Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY.12	Dr. Michael Crump
5:05 – 5:20	Open Label Phase III Randomized Controlled Trial Comparing Taxane-Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women with HER2+ Metastatic Breast Cancer: Final Analysis of NCIC CTG MA.31 / GSK EGF 108919	Dr. Karen Gelmon
5:20 – 5:35	ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer	Dr. Frances Shepherd
5:35 – 5:50	A Randomized Trial of Single Versus Multiple Fractions for Re-irradiation of Painful Bone Metastases: NCIC CTG SC.20	Dr. Edward Chow
5:50 – 6:05	Effect of Metformin vs. Placebo on Weight and Metabolic Factors in Initial Patients Enrolled onto NCIC CTG MA.32 – A Multicenter Adjuvant Randomized Controlled Trial in Early Stage Breast Cancer	Dr. Pam Goodwin